Skip to main content

Advertisement

ADVERTISEMENT

Medication Treatments

News
06/02/2020
Braeburn has requested final approval from the U.S. Food and Drug Administration for Brixadi, an injectable form of buprenorphine with weekly and monthly formulations. Brixadi was tentatively approved by the FDA for treatment of moderate to...
Braeburn has requested final approval from the U.S. Food and Drug Administration for Brixadi, an injectable form of buprenorphine with weekly and monthly formulations. Brixadi was tentatively approved by the FDA for treatment of moderate to...
Braeburn has requested final...
06/02/2020
Addiction Professional
News
05/28/2020
A synthetic molecule developed by researchers at Duke University has shown the ability to selectively dampen physiological rewards of cocaine in mice, according to research published in the journal Cell on Thursday.
A synthetic molecule developed by researchers at Duke University has shown the ability to selectively dampen physiological rewards of cocaine in mice, according to research published in the journal Cell on Thursday.
A synthetic molecule developed...
05/28/2020
Addiction Professional
News
05/11/2020
A study of nearly 400 clinicians at four urban academic emergency departments found that about 1 in 5 emergency department clinicians say they are ready to offer buprenorphine to patients in need for the treatment of opioid use disorder. The...
A study of nearly 400 clinicians at four urban academic emergency departments found that about 1 in 5 emergency department clinicians say they are ready to offer buprenorphine to patients in need for the treatment of opioid use disorder. The...
A study of nearly 400 clinicians...
05/11/2020
Addiction Professional
News
04/22/2020
A long-term safety study of the extended-release formulation of buprenorphine for opioid use disorder (OUD) has identified a safety profile comparable to that of traditional sublingual buprenorphine. Published online this month in the Journal...
A long-term safety study of the extended-release formulation of buprenorphine for opioid use disorder (OUD) has identified a safety profile comparable to that of traditional sublingual buprenorphine. Published online this month in the Journal...
A long-term safety study of the...
04/22/2020
Addiction Professional
News
04/15/2020
As a young pharmacy intern, Daniel Ventricelli received an unforgettable lesson in how pharmacies can sometimes pose barriers to accessing potentially life-saving buprenorphine for patients with opioid use disorder (OUD).
As a young pharmacy intern, Daniel Ventricelli received an unforgettable lesson in how pharmacies can sometimes pose barriers to accessing potentially life-saving buprenorphine for patients with opioid use disorder (OUD).
As a young pharmacy intern,...
04/15/2020
Addiction Professional
News
04/14/2020
Community addiction treatment programs and local jails can build on some existing similarities to form partnerships providing much-needed medication treatment services to more inmates, two correctional health leaders said at the virtual Rx...
Community addiction treatment programs and local jails can build on some existing similarities to form partnerships providing much-needed medication treatment services to more inmates, two correctional health leaders said at the virtual Rx...
Community addiction treatment...
04/14/2020
Addiction Professional
News
04/03/2020
Results of a study suggest that extended treatment with buprenorphine for opioid use disorder (OUD) improves the likelihood of sustained abstinence and also enhances patient quality-of-life outcomes.
Results of a study suggest that extended treatment with buprenorphine for opioid use disorder (OUD) improves the likelihood of sustained abstinence and also enhances patient quality-of-life outcomes.
Results of a study suggest that...
04/03/2020
Addiction Professional
News
03/24/2020
The American Society of Addiction Medicine (ASAM) has released a major update to its National Practice Guideline for the Treatment of Opioid Use Disorder, strongly stating that other components of treatment should not function to impede...
The American Society of Addiction Medicine (ASAM) has released a major update to its National Practice Guideline for the Treatment of Opioid Use Disorder, strongly stating that other components of treatment should not function to impede...
The American Society of...
03/24/2020
Addiction Professional
Three Steps to Overcoming Obstacles to MAT
03/16/2020
Medication-assisted treatment (MAT) is widely considered the gold standard for treating opioid use disorder (OUD) when combined with behavioral therapies. Yet the number of primary care providers practicing MAT remains stubbornly low. Medical...
Medication-assisted treatment (MAT) is widely considered the gold standard for treating opioid use disorder (OUD) when combined with behavioral therapies. Yet the number of primary care providers practicing MAT remains stubbornly low. Medical...
Medication-assisted treatment...
03/16/2020
Addiction Professional
News
03/05/2020
Besides showing that agonist medications for opioid use disorder (OUD) strongly protect against overdose death during treatment, a newly published data analysis has found that the period after medication treatment ends carries substantial...
Besides showing that agonist medications for opioid use disorder (OUD) strongly protect against overdose death during treatment, a newly published data analysis has found that the period after medication treatment ends carries substantial...
Besides showing that agonist...
03/05/2020
Addiction Professional

Advertisement

Advertisement